Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Johnson & Johnson Revenue & Financial Statements
Johnson & Johnson reported revenue of $94.2B for the fiscal year ended December 28, 2025, up 6.0% year over year, with net income of $26.8B and diluted EPS of $11.03.
- Company
- Johnson & Johnson JNJ · NYSE
- Latest fiscal year
- FY ended Dec 28, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 93.8B | 94.9B | 85.2B | 88.8B | 94.2B |
| Cost of revenue | 29.9B | 31.1B | 26.6B | 27.5B | 30.3B |
| Gross profit | 63.9B | 63.9B | 58.6B | 61.4B | 63.9B |
| Operating income | — | — | — | — | — |
| Pretax income | 6.1B | 5.4B | (2.0B) | (458.0M) | 17.3B |
| Net income | 20.9B | 17.9B | 35.2B | 14.1B | 26.8B |
| Diluted EPS | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| EBITDA | — | — | — | — | — |
Quarterly
| USD | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.4B | 22.5B | 22.5B | 21.9B | 23.7B | 24.0B | 24.6B | 24.1B |
| Cost of revenue | 6.9B | 7.0B | 7.1B | 7.4B | 7.6B | 7.3B | 8.0B | 8.1B |
| Gross profit | 15.6B | 15.5B | 15.4B | 14.5B | 16.1B | 16.7B | 16.6B | 16.0B |
| Operating income | — | — | — | — | — | — | — | — |
| Pretax income | 5.7B | 3.3B | 3.9B | 13.6B | 6.5B | 7.5B | 5.0B | 6.0B |
| Net income | 4.7B | 2.7B | 3.4B | 11.0B | 5.5B | 5.2B | 5.1B | 5.2B |
| Diluted EPS | 1.93 | 1.11 | 1.41 | 4.54 | 2.29 | 2.12 | 2.09 | 2.14 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 180.1B | — | 199.2B | — |
| Current assets | — | 55.9B | — | 55.6B | — |
| Cash & equivalents | — | 24.1B | — | 19.7B | — |
| Total liabilities | — | 108.6B | — | 117.7B | — |
| Current liabilities | — | 50.3B | — | 54.1B | — |
| Long-term debt | — | 30.7B | — | 39.4B | — |
| Total debt | — | 36.6B | — | 47.9B | — |
| Stockholders’ equity | — | — | — | — | — |
| Net debt | — | 12.5B | — | 28.2B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 23.4B | 21.2B | 22.8B | 24.3B | 24.5B |
| Investing cash flow | (8.7B) | (12.4B) | 878.0M | (18.6B) | (23.6B) |
| Financing cash flow | (14.0B) | (8.9B) | (15.8B) | (3.1B) | (5.5B) |
| Capital expenditure | 3.7B | 4.0B | 4.5B | 4.4B | 4.8B |
| Free cash flow | 19.8B | 17.2B | 18.2B | 19.8B | 19.7B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 1.1B | 1.1B | 1.2B | 1.2B | 1.4B |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every JNJ filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.